logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Opioid Antagonist class drugs

    FiltersReset Filters
    11 results

    • buprenorphine and naloxone

      (Buprenorphine and Naloxone)
      Rhodes Pharmaceuticals L.P.
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, to be used alongside counseling and psychosocial support as part of a comprehensive treatment plan.

    • buprenorphine hydrochloride and naloxone hydrochloride dihydrate

      (Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate)
      SpecGx LLC
      Usage: Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence, to be used alongside a comprehensive treatment plan that incorporates counseling and psychosocial support.

    • contrave

      (naltrexone hydrochloride and bupropion hydrochloride)
      Nalpropion Pharmaceuticals LLC
      Usage: CONTRAVE is indicated for chronic weight management in adults with a BMI of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) with weight-related comorbid conditions, as an adjunct to diet and exercise. Safety with other weight loss products is not established.

    • lybalvi

      (olanzapine and samidorphan L-malate)
      Alkermes, Inc.
      Usage: LYBALVI is indicated for the treatment of schizophrenia in adults and for Bipolar I disorder in adults, including acute treatment of manic or mixed episodes (as monotherapy or adjunct to lithium/valproate) and maintenance monotherapy.

    • movantik

      (naloxegol oxalate)
      RedHill Biopharma Ltd
      Usage: MOVANTIK® is indicated for treating opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including those with pain related to prior cancer or its treatment, who do not require frequent opioid dosage increases.

    • naloxone hydrochloride

      (Naloxone Hydrochloride)
      BPI Labs LLC
      Usage: Naloxone hydrochloride injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression from natural and synthetic opioids. It also aids in diagnosing suspected opioid overdose and may be used as an adjunct to increase blood pressure in septic shock management.

    • relistor

      (Methylnaltrexone bromide)
      Salix Pharmaceuticals, Inc.
      Usage: RELISTOR is indicated for treating opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced illness requiring opioid escalation for palliative care, including those with chronic pain related to prior cancer or its treatment.

    • suboxone

      (buprenorphine hydrochloride, naloxone hydrochloride)
      INDIVIOR INC.
      Usage: SUBOXONE sublingual film is indicated for the treatment of opioid dependence and should be used as part of a comprehensive treatment plan that includes counseling and psychosocial support.

    • symproic

      (naldemedine)
      BioDelivery Sciences International Inc
      Usage: SYMPROIC is indicated for treating opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including those with pain related to prior cancer or its treatment, who do not need frequent opioid dosage increases.

    • vivitrol

      (naltrexone)
      Alkermes, Inc.
      Usage: VIVITROL is indicated for the treatment of alcohol dependence in patients able to abstain before starting therapy and for preventing relapse to opioid dependence following detoxification. It should be used as part of a comprehensive management program that includes psychosocial support.